Trovagene Inc (TROV) 5.63 $TROV Trovagene Schedules

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2016 at 5:03 AM

Trovagene Inc (TROV) 5.63 $TROV

Trovagene Schedules Release of Second Quarter 2016 Financial Results and Investor Conference Call
PR Newswire - Tue Jul 26, 7:45AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, announced today that it will report financial results for the second quarter ended June 30, 2016 on Thursday, August 4, 2016 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time).
TROV: 5.63 (+0.18)

Diagnostic Performance of Urinary EGFR Testing in Lung Cancer Patients Published in Journal of Thoracic Oncology
PR Newswire - Tue Jul 26, 7:30AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, today announced the publication of study results that demonstrate the clinical and analytical validity of the Trovera(TM) urine- and blood based liquid biopsy tests to assess EGFR T790M mutational status http://www.jto.org/article/S1556-0864(16)30587-1/abstract
TROV: 5.63 (+0.18)

TrovaGene Inks Partnership with USC Norris Cancer Center
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 5:05PM CDT
TrovaGene (TROV) recently inked a partnership with the USC Norris Comprehensive Cancer Center, which aims at building a standardized framework for the use of the Trovera system.
ENZ: 6.97 (+0.27), INVA: 12.87 (+1.17), TROV: 5.63 (+0.18), FCSC: 1.09 (unch)

/C O R R E C T I O N -- Trovagene, Inc./
PR Newswire - Mon Jul 11, 9:42AM CDT
In the news release, Trovagene to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference, issued 05-Jul-2016 by Trovagene, Inc. over PR Newswire, we are advised by the company that the second paragraph, first sentence, should read "Trovagene is scheduled to present on Wednesday, July 13, 2016 at 1:30 pm EDT." rather than "Trovagene is scheduled to present on Wednesday, July 13, 2016 at 3:30 pm EDT." as originally issued inadvertently. The complete, corrected release follows:
TROV: 5.63 (+0.18)

TrovaGene Inks Partnership with University of Michigan
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 3:31PM CDT
TrovaGene Inc. (TROV) is collaborating with the University of Michigan to conduct a multi-phased research program using Trovera KRAS ctDNA liquid biopsy test.
ABMD: 117.97 (+2.94), MASI: 52.97 (+0.39), TROV: 5.63 (+0.18), MLAB: 115.63 (-3.92)

Trovagene and University of Michigan Enter into Collaboration for Monitoring and Early Detection of Pancreatic Cancer
PR Newswire - Wed Jul 06, 8:58AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, today announced the initiation of a multi-phased collaborative research program with the University of Michigan Comprehensive Cancer Center utilizing the Trovera(TM) KRAS ctDNA liquid biopsy test.
TROV: 5.63 (+0.18)

TrovaGene: Trovera Liquid Biopsy Urine Test Results Positive (Revised)
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 3:37AM CDT
TrovaGene Inc. (TROV) recently presented clinical results demonstrating the effectiveness of its Trovera non-invasive test in detecting EGFR T790M mutations.
IRMD: 19.36 (+0.80), MASI: 52.97 (+0.39), TROV: 5.63 (+0.18), EXAC: 27.03 (+0.15)

TrovaGene: Trovera Liquid Biopsy Urine Test Results Positive
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:39AM CDT
TrovaGene Inc. (TROV) recently presented clinical results demonstrating the effectiveness of its Trovera non-invasive test in detecting EGFR T790M mutations in the urine of patients with non-small cell lung cancer (NSCLC).
IRMD: 19.36 (+0.80), MASI: 52.97 (+0.39), TROV: 5.63 (+0.18), EXAC: 27.03 (+0.15)

ASCO Oral Presentation Demonstrates Trovagene's Liquid Biopsy Urine Test Detects EGFR T790M Mutations in Patients with Non-Small Cell Lung Cancer
PR Newswire - Mon Jun 06, 10:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, announced the presentation of clinical results demonstrating highly sensitive detection of EGFR T790M mutations in the urine of patients with non-small cell lung cancer. The oral presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, entitled Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients treated with rociletinib, was delivered today by Heather Wakelee, M.D. of Stanford University http://abstracts.asco.org/176/AbstView_176_167439.html.
TROV: 5.63 (+0.18)

Why These Stocks are Under the Investor Community's Microscope? - Bruker, Quintiles Transnational Holdings, iKang Healthcare Group, and TrovaGene
PR Newswire - Wed Jun 01, 7:20AM CDT
In today's pre-market research, ActiveWallSt.com has selected the following Medical Laboratories and Research stocks for your evaluation: Bruker Corp. (NASDAQ: BRKR), Quintiles Transnational Holdings Inc. (NYSE: Q), iKang Healthcare Group Inc. (NASDAQ: KANG), and TrovaGene Inc. (NASDAQ: TROV). Access these equities free technical alerts at:
Q: 77.64 (-0.28), TROV: 5.63 (+0.18), KANG: 18.46 (unch), BRKR: 24.92 (+0.44)

Large Clinical Data Set in Lung Cancer Featuring Trovagene's Precision Cancer Monitoring® Platform Selected for Oral Presentation at the 2016 ASCO Annual Meeting
PR Newswire - Thu May 19, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that diagnostic performance results using the Company's Precision Cancer Monitoring® platform to detect and monitor EGFR T790M in the urine of non-small cell lung cancer (NSCLC) patients will be the subject of an oral presentation given by Heather Wakelee, M.D., Stanford University Medical Center, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstracts for the ASCO meeting were released last night, and can be viewed at http://abstracts.asco.org/
TROV: 5.63 (+0.18)

TrovaGene (TROV) Q1 Loss Wider than Expected, Stock Gains
Zacks Equity Research - Zacks Investment Research - Wed May 11, 7:16AM CDT
TrovaGene Inc (TROV) reported adjusted loss of 36 cents per share in the first quarter of 2016, wider than the year-ago loss of 33 cents.
TROV: 5.63 (+0.18), TECH: 112.42 (+1.64), EXAC: 27.03 (+0.15), NVRO: 82.70 (+1.05)

Trovagene reports 1Q loss
Automated Insights - Tue May 10, 4:25PM CDT
SAN DIEGO (AP) _ Trovagene Inc. (TROV) on Tuesday reported a loss of $10.3 million in its first quarter.
TROV: 5.63 (+0.18)

Trovagene Announces First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 3:05PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months ended March 31, 2016.
TROV: 5.63 (+0.18)

Lifshitz & Miller Law Firm Announces Investigation of Apigee Corporation, Mentor Graphics Corp., PayPal Holdings Inc., Performance Sports Group, Ltd., PJT Partners, Inc., and Trovagene, Inc.
PR Newswire - Thu May 05, 12:13PM CDT
Apigee Corporation (APIC)
PSG: 3.33 (-0.06), APIC: 12.44 (-0.06), MENT: 21.36 (-0.02), TROV: 5.63 (+0.18), PJT: 25.53 (-0.58), PYPL: 37.24 (+0.02)

Trovagene Schedules Release of First Quarter 2016 Financial Results and Investor Conference Call
PR Newswire - Tue May 03, 7:15AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the first quarter ended March 31, 2016 on Tuesday, May 10, 2016 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time).
TROV: 5.63 (+0.18)

Trovagene to Present at the 41st Annual Deutsche Bank Healthcare Conference
PR Newswire - Thu Apr 28, 7:15AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that its Chief Scientific Officer, Mark Erlander, Ph.D. will present a corporate overview at the 41st Annual Deutsche Bank Healthcare Conference taking place May 4-5, 2016 at the InterContinental Hotel in Boston, MA.
TROV: 5.63 (+0.18), DB: 13.44 (+0.19)

What's in Store for TrovaGene (TROV) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 8:16AM CDT
TrovaGene Inc. (TROV) is expected to release first-quarter 2016 results on May 3.
BDX: 176.00 (+0.04), PRXL: 66.85 (+0.02), ALGN: 89.15 (+3.87), TROV: 5.63 (+0.18)

Trovagene Appoints Bill Welch as Chief Executive Officer
PR Newswire - Mon Apr 25, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced the appointment of William (Bill) Welch as Chief Executive Officer, effective immediately. In addition, the Company announced that Matthew Posard, the Company's Chief Commercial Officer, has left the Company.
TROV: 5.63 (+0.18)

TrovaGene Inks Strategic Partnership with Stratose, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 12:10PM CDT
Shares of TrovaGene Inc. (TROV) climbed 1.8% (9 cents) to close at $5.10 on Apr 11, following the announcement of a new strategic agreement with Stratose Inc.
TROV: 5.63 (+0.18), GILD: 79.47 (-1.77), AMAG: 26.53 (-0.06), ANIK: 49.92 (+0.70)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

OmniActive's Fenavari: A New Era in Women's Health

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...

Celebree Gains Franchise Momentum: A New Frontier

The Climb: Celebree Schools on the Rise Here's a nugget in the franchise world that's causing a stir: Celebree School is making moves up the Franchise Times Top 400. When we're talking about a hop, skip, and jump through 84 spots since 2023, you can't help but notice. It's the third year in a row they're climbing this ladder, and it's making ripples. Franchise Expansion...

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Home Buying: Unmasking All the Real Budget Costs

Home Buying: More Costs Than Meets the Eye Let's face it, buying a home is no stroll in the park. It's a tangled web of numbers and surprises that can leave even the savviest buyer in a daze. Thank goodness for articles like the one from HelloNation featuring Serena LoPiccolo-Smith, which make the invisible visible when it comes to the financial intricacies of home...

Partner Valuation Advisors Bolsters Team with Eichman

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Simple Home Upgrades That Boost Value Fast

Transform Your Home's Curb Appeal Without Breaking The Bank Every homeowner knows that feeling when you look at your house one day and think, "This could use a little something." Say you're strolling through a neighborhood in Fulton, N.Y., and notice a gem. It's not a brand new build, but it gleams with character. You bet it's had a few smart touches that could apply...

Paradigm Therapeutics: A Beacon in Rare Diseases

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...

Dr. Anderson’s Journey: Leadership with Faith and Service

A Life Shaped by Service Dr. Howard Anderson isn't just another name in a glossy award roster—he's a powerhouse of leadership, a chaplain of compassion, and a soldier in spirit. Honored as a Pinnacle Professional Member of The Inner Circle of Excellence, his recognition feels less like an accolade and more like a testament to a life committed to serving others. The...

Special Needs Group Partners with MAST to Enhance Accessibility

Accessible Travel Takes the Spotlight Ah, the travel biz—just when you think you’ve got it all figured out, along comes a partnership like this to shake things up. Special Needs Group, the big cheese in mobility and medical equipment rentals, is teaming up with MAST Travel Network. Together, they're rolling out initiatives to make the world a bit more accessible, even...